Navigation Links
CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/30/2007

VIENNA, Va., Oct. 30 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the Rodman & Renshaw 9th Annual Healthcare Conference being held at the New York Plaza Hotel from November 5-7, 2007. The presentation will be focused on its Phase III cancer product Multikine(R) which is the first biotech cancer product seeking to become a new first line standard of care treatment in cancer.

Mr. Kersten's presentation will be on Wednesday, November 7th, at 1:40 p.m. EDT. The presentation will be webcast live with slides and archived for 90 days after the conference. The webcast can be accessed at http://www.wsw.com/webcast/rrshq12/cvm or http://www.cel-sci.com.

About CEL-SCI's Phase III Cancer Drug Multikine:

In Phase II clinical trials Multikine was shown to be safe and well- tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS." Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
3. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
4. The Past, Present and Future of HLA Typing
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 CBG ... the PW Series Solvent Recycling Systems, specifically designed ... full integration with new and existing vapor degreasers, ... produces consistently-fresh solvent through continuous recycling and recovers ... --> --> Precision parts ...
(Date:2/8/2016)... 2016 --> ... "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, ... Surgery, Ophthalmology, Gynecology) - Global Forecasts to 2020", published ... the forecast period of 2015 to 2020. The market ... CAGR of 10.5% from 2015 to 2020. ...
(Date:2/8/2016)... EAST NORRITON, Pa. , Feb. 8, 2016 ... acquisition of November Research Group (NRG),s pharmacovigilance ... of pharmacovigilance system-related consulting services and an Oracle ... regulatory compliance services to Life Sciences companies. ... acquisition strengthens and expands HighPoint,s life sciences capabilities ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... Shark Finds and Kevin Harrington, and the Product Managers ... , GRIP-DRY is a newly patented product that has solved some of the basic problems ... and early morning dew or right after a rain shower, might understand the struggle of ...
(Date:2/8/2016)... ... February 08, 2016 , ... CURE Media Group , the nation’s ... Multiple Myeloma Heroes Awards event , which will annually honor individuals making heroic ... with MM. The MM Heroes Awards nomination process is officially open through ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , ... Food & Beverage and Dietary Supplement market segments across the ... USA geographies east of the Rocky Mountains since 2012. Consistent performance in ...
(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... Angeles, CA (PRWEB) , ... February 08, 2016 , ... A man who has struggled ... of Freedom Laser Therapy , was determined to find solutions to his problems – ... of Inventors Digest is ready to introduce his breakthrough inventions to the world ...
Breaking Medicine News(10 mins):